A Phase 3 interventional study of Levomilnacipran ER and Levomilnacipran ER in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 38 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-10-25.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.
Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 3rd largest by enrollment, is one of 4 that started in 2009, is one of 10 in phase 3, and was the 1st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →
Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 724 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 472 across the 14 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
53 studies in Depressive Disorder, Major by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 50 finished, 37 (74%) have results posted.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 11th largest by enrollment, is one of 5 that started in 2009, is one of 31 in phase 3, and was the 9th registered.
AbbVie’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a history of meeting criteria for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
Drug: Levomilnacipran ER
80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
Drug: Levomilnacipran ER
120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
Drug: Levomilnacipran ER
Matching placebo capsules, oral administration, once daily.
Drug: Placebo
Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
Matching placebo capsules, oral administration, once daily for 8 weeks.
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity for all measured symptoms).
Time frame: From Baseline to Week 8
Change in Sheehan Disability Scale (SDS) Total Score
The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate functional impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe for all measured symptoms)
Time frame: From Baseline to Week 8
Patient recruitment at 38 study centers located in the United States during a 17 month period from September 2009 to February 2011.
| Milestone | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg |
|---|---|---|---|---|
| Started | 176 | 178 | 179 | 180 |
| Completed | 138 | 130 | 121 | 117 |
| Not completed | 38 | 48 | 58 | 63 |
| Withdrew: Adverse event | 3 | 13 | 26 | 12 |
| Withdrew: Lack of efficacy | 7 | 4 | 1 | 3 |
| Withdrew: Protocol violation | 9 | 5 | 9 | 10 |
| Withdrew: Withdrawal by subject | 9 | 12 | 11 | 23 |
| Withdrew: Lost to follow-up | 10 | 14 | 8 | 15 |
| Withdrew: Other reasons | 0 | 0 | 3 | 0 |
The MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity for all measured symptoms).
| Units on a scale | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg |
|---|---|---|---|---|
| Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -11.6 ± 0.97 | -14.8 ± 0.99 | -15.6 ± 1.00 | -16.5 ± 1.02 |
The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate functional impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe for all measured symptoms)
| units on a scale | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg |
|---|---|---|---|---|
| Change in Sheehan Disability Scale (SDS) Total Score | -7.2 ± 0.74 | -8.6 ± 0.75 | -9.7 ± 0.77 | -9.7 ± 0.78 |
Collected over Adverse event data was collected over a 20 month period from September 2009 to June 2011 at 38 study sites.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/176 (0.6%) | 66/176 (37.5%) |
| Levomilnacipran ER 40 mg | — | 3/178 (1.7%) | 110/178 (61.8%) |
| Levomilnacipran ER 80 mg | — | 2/179 (1.1%) | 122/179 (68.2%) |
| Levomilnacipran ER 120 mg | — | 1/180 (0.6%) | 112/180 (62.2%) |
| Event | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg |
|---|---|---|---|---|
| Premature babyPregnancy, puerperium and perinatal conditions | 0/108 | 0/122 | 0/111 | 1/106 |
| Small for dates babyPregnancy, puerperium and perinatal conditions | 0/108 | 0/122 | 0/111 | 1/106 |
| Pre-eclampsiaPregnancy, puerperium and perinatal conditions | 0/108 | 0/122 | 1/111 | 0/106 |
| PneumoniaInfections and infestations | 1/176 | 0/178 | 0/179 | 0/180 |
| AggressionPsychiatric disorders | 0/176 | 1/178 | 0/179 | 0/180 |
| Chest PainGeneral disorders | 0/176 | 1/178 | 0/179 | 0/180 |
| Deep vein thrombosisVascular disorders | 0/176 | 1/178 | 0/179 | 0/180 |
| Suicide AttemptPsychiatric disorders | 0/176 | 1/178 | 0/179 | 0/180 |
| Cytomegalovirus mononucleosisInfections and infestations | 0/176 | 0/178 | 1/179 | 0/180 |
| Event | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/176 | 19/178 | 39/179 | 23/180 |
| HeadacheNervous system disorders | 20/176 | 29/178 | 36/179 | 27/180 |
| Dry mouthGastrointestinal disorders | 17/176 | 20/178 | 12/179 | 27/180 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 4/176 | 9/178 | 24/179 | 10/180 |
| ConstipationGastrointestinal disorders | 7/176 | 19/178 | 18/179 | 23/180 |
| Heart rate increasedInvestigations | 3/176 | 18/178 | 11/179 | 17/180 |
| DizzinessNervous system disorders | 8/176 | 10/178 | 17/179 | 14/180 |
| Erectile dysfunctionReproductive system and breast disorders | 2/68 | 3/56 | 2/68 | 7/74 |
| Upper respiratory tract infectionInfections and infestations | 10/176 | 14/178 | 11/179 | 4/180 |
| NasopharyngitisInfections and infestations | 10/176 | 11/178 | 9/179 | 7/180 |
A total of 724 patients were randomized to receive double-blind treatment (Randomized Population); 713 patients received at least 1 dose of treatment (Safety Population). The demographic analyses of the baseline participants is based on the Safety Population
| Age Continuous(years) | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg | Total |
|---|---|---|---|---|---|
| Mean | 43.1 ± 11.3 | 41.6 ± 13.1 | 41.0 ± 12.8 | 40.3 ± 11.9 | 41.1 ± 12.3 |
| Age, Customized(participants) | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg | Total |
|---|---|---|---|---|---|
| 18 years to 19 years | 1 | 2 | 4 | 2 | 9 |
| 20 years to 29 years | 31 | 43 | 44 | 42 | 160 |
| 30 years to 39 years | 47 | 34 | 33 | 38 | 152 |
| 40 years to 49 years | 44 | 36 | 48 | 46 | 174 |
| 50 years to 59 years | 46 | 48 | 36 | 41 | 171 |
| 60 years to 65 years | 7 | 15 | 14 | 11 | 47 |
| Sex: Female, Male(Participants) | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg | Total |
|---|---|---|---|---|---|
| Female | 108 | 122 | 111 | 106 | 447 |
| Male | 68 | 56 | 68 | 74 | 266 |
| Race/Ethnicity, Customized(participants) | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg | Total |
|---|---|---|---|---|---|
| White | 134 | 133 | 129 | 130 | 526 |
| Black or African American | 29 | 36 | 39 | 41 | 145 |
| Asian | 8 | 3 | 5 | 3 | 19 |
| American Indian or Alaska native | 1 | 0 | 2 | 1 | 4 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Other | 3 | 6 | 4 | 4 | 17 |
| Hispanic or Latino | 20 | 22 | 28 | 22 | 92 |
| Not Hispanic or Latino | 156 | 155 | 151 | 158 | 620 |
| Region of Enrollment(participants) | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg | Total |
|---|---|---|---|---|---|
| United States | 176 | 178 | 179 | 180 | 713 |
| Weight(kg) | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg | Total |
|---|---|---|---|---|---|
| Mean | 83.8 ± 19.3 | 79.5 ± 17.1 | 83.0 ± 17.3 | 84.2 ± 18.6 | 82.6 ± 18.1 |
| Body Mass Index (BMI)(Kilograms Per Meter Squared) | Placebo | Levomilnacipran ER 40 mg | Levomilnacipran ER 80 mg | Levomilnacipran ER 120 mg | Total |
|---|---|---|---|---|---|
| Mean | 29.0 ± 5.8 | 28.0 ± 5.3 | 28.9 ± 5.4 | 29.2 ± 5.4 | 28.8 ± 5.5 |
The record gives a start of Sep 2009 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 2 years 5 months after primary completion. A results delay was requested in Jul 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levomilnacipran